Overview Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs) Status: Completed Trial end date: 2005-10-01 Target enrollment: Participant gender: Summary This is an open-label, multi-center, long-term, (open-ended) safety study with 125 mg per day of azimilide in patients who completed protocol 2000098. Phase: Phase 3 Details Lead Sponsor: Forest LaboratoriesWarner ChilcottTreatments: Azimilide